Anagrelide
- Generic Name
- Anagrelide
- Brand Names
- Xagrid, Agrylin, Anagrelide Viatris (previously Anagrelide Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C10H7Cl2N3O
- CAS Number
- 68475-42-3
- Unique Ingredient Identifier
- K9X45X0051
- Background
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. busulfan, hydroxyur...
- Indication
Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.
- Associated Conditions
- Thrombocythemia
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.